- Investor's Business Daily•7 minutes ago
Kite's pipeline is unfolding even as investors undervalue the stock, RBC analyst Michael Yee said Thursday.
- Zacks•6 hours ago
Given the current scenario of increased political, media and public pressure on drug pricing, it makes sense to zero in on companies that are in the biosimilars business.
- Barrons.com•6 hours ago
Biotech stocks like Celgene (CELG), Amgen (AMGN), Gilead Sciences (GILD), and Biogen (BIIB) will be reporting earnings over the next few weeks. BMO Capital Markets analysts M. Ian Somaiya and Do Kim wonder ...
Amgen Inc. (AMGN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||161.87 x 200|
|Ask||161.88 x 100|
|Day's Range||161.00 - 163.33|
|52wk Range||139.02 - 176.85|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||16.53|
|Avg Vol (3m)||2,763,176|
|Dividend & Yield||4.00 (2.46%)|